君实生物 · Junshi Biosciences
← News archive

· Business development

Junshi and Fosun Wanbang sign a Greater China agreement for roconkibart

Junshi announced a licensing agreement with Fosun Wanbang for roconkibart, an antibody targeting IL-17A.

The agreement covers development, regulatory registration, manufacturing and commercialization in Greater China. Fosun Wanbang is a subsidiary of Fosun Pharma.

Read the full company release